Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by juniorcalon Dec 04, 2018 1:11am
121 Views
Post# 29058906

The Company Not even own a 100% of Marigold lol

The Company Not even own a 100% of Marigold lol Marigold Receives Five Conditional Cannabis Related Licenses TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or Scythian) (TSXV:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) is pleased to announce that it has entered into a binding letter of intent dated March 21, 2018 (Letter of Intent) to acquire Marigold Acquisitions Inc. (the Acquisition). The Acquisition will result in Scythian becoming a major stakeholder of Marigold Projects Jamaica Ltd. (Marigold), a Jamaican company, which has received conditional licenses to cultivate, process, sell and provide therapeutic or spa services utilizing cannabis products. In consideration, Scythian will issue 1,500,000 common shares at the current price per share of $23.00 to the selling parties. Following completion of the Acquisition, the Marigold Receives Five Conditional Cannabis Related Licenses TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or Scythian) (TSXV:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) is pleased to announce that it has entered into a binding letter of intent dated March 21, 2018 (Letter of Intent) to acquire Marigold Acquisitions Inc. (the Acquisition). The Acquisition will result in Scythian becoming a major stakeholder of Marigold Projects Jamaica Ltd. (Marigold), a Jamaican company, which has received conditional licenses to cultivate, process, sell and provide therapeutic or spa services utilizing cannabis products. In consideration, Scythian will issue 1,500,000 common shares at the current price per share of $23.00 to the selling parties. Following completion of the Acquisition, the Company will own a 49% interest in Marigold as well as a 95% royalty interest in the net revenues from products sold by Marigold as well as a 95% royalty interest in the net revenues from products sold by Marigold
Bullboard Posts